R&D News | pharmaphorum

News

Herpes simplex virus (HSV-2) capsid visualisation

GSK drops HSV jab, leaving rival mRNA shots in pole position

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.

News

Dupixent delivers in two skin disease trials

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f

News

Meet MILTON, AZ's AI that can predict 1,000+ diseases

A machine-learning tool developed by AstraZeneca and trained on UK Biobank health record data could predict over 1,000 diseases, before diagnosis, according to a paper in Nature Genetics.

News

Study backs role of Novo Nordisk obesity drug in children

A clinical trial has backed the safety and efficacy of one of Novo Nordisk's weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI).

News

Lungs computer graphic in palm of a doctor's hand

Roivant's new 'vant' emerges to advance Bayer lung drug

Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed from Bayer in a deal worth up to $294 million.

News

Viridian takes aim at Amgen's Tepezza with veligrotug data

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian

GSK drops HSV jab, leaving rival mRNA shots in pole position

Dupixent delivers in two skin disease trials

Meet MILTON, AZ's AI that can predict 1,000+ diseases

Study backs role of Novo Nordisk obesity drug in children

Roivant's new 'vant' emerges to advance Bayer lung drug

Viridian takes aim at Amgen's Tepezza with veligrotug data

UK's Claret Capital raises €575m for European biotechs

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks